Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,191.37 -8.32 -0.26%
FTSE 100 6,672.63 -9.13 -0.14%
DAX 9,572.80 -27.29 -0.28%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Sigma® Life Science Launches Tough Decoy (TuD) miRNA Inhibitors in Collaboration with University of Tokyo Drs. Hideo Iba and



      Sigma® Life Science Launches Tough Decoy (TuD) miRNA Inhibitors in
 Collaboration with University of Tokyo Drs. Hideo Iba and Takeshi Haraguchi

PR Newswire

ST. LOUIS, Feb. 13, 2013

ST. LOUIS, Feb. 13, 2013 /PRNewswire/ -- Sigma-Aldrich^® Corporation (NASDAQ:
SIAL) today announced that Sigma Life Science, its innovative biological
products and services business, through an exclusive collaboration with Drs.
Hideo Iba and Takeshi Haraguchi at the University of Tokyo, released MISSION^®
Synthetic and Lentiviral microRNA Inhibitors based upon the Tough Decoy (TuD)
design for the long-term suppression of any miRNA endogenous to humans or
mice. Custom designs for other species are available upon request. Each
microRNA inhibitor is designed using a proprietary algorithm that evaluates
all possible sequences for the design predicted to best maintain the TuD
structure, providing maximal miRNA recognition and binding. For more
information, visit www.sigma.com/inhibitors.  

Naturally-occurring miRNAs inhibit translation of a large percentage of mRNAs
encoding human proteins and play pivotal roles in oncogenesis, development,
cell differentiation, and immune responses.  Iba and Haraguchi invented TuD
RNAs^1,2 as a more potent tool to suppress specific miRNAs and thus
investigate their biological functions.

In contrast to current approaches that use single-stranded RNAs, such as
sponge decoys and locked nucleic acids, TuD RNAs are double-stranded. This,
along with a stem-loop stabilized secondary structure, resists cellular
nuclease degradation and facilitates sustained miRNA inhibition for longer
than one month. In addition, both strands of a TuD RNA contain an miRNA
binding site for more efficient sequestration of target miRNAs at lower,
nanomolar concentrations.

"Drs. Iba and Haraguchi's Tough Decoy RNAs are an elegant and more practical
tool for exploring the impact of microRNA gene regulation on human disease.
Sigma Life Science's mission is to support this field's rapid development by
making keystone technologies like this broadly accessible," says Dr. Supriya
Shivakumar, Director of Emerging Technologies at Sigma Life Science.

Sigma Life Science provides the TuD RNAs in both synthetic and lentiviral
formats to support transient miRNA knockdown as well as long-term miRNA
suppression without repeated transfections. The miRNA binding sites are
designed using human and mouse sequence data from the most recent version of
miRBase (v.19).

Many other tools for miRNA screening, identification, and validation
experiments are available from Sigma Life Science. These include synthetic
human miRNA mimics, a miRNA isolation kit, a method to identify the specific
gene(s) that a miRNA targets (licensed exclusively from Dr. Joop Gaken at
King's College London), and a library of human 3′UTRs for validating many
miRNA gene targets.

For more information, visit www.sigma.com/mirna.

(1) Haraguchi, T., et al., Vectors expressing efficient RNA decoys achieve the
long-term suppression of specific microRNA activity in mammalian cells.
Nucleic Acids Res., 37, (2009).

(2) Haraguchi, T, et al. A potent 2'-O-methylated RNA-based microRNA inhibitor
with unique secondary structures. Nucleic Acids Res. 2012 Apr;40(8):e58. Epub
2012 Jan 17.

Cautionary Statement: The foregoing release contains forward-looking
statements that can be identified by terminology such as "more potent," "more
efficient," or similar expressions, or by expressed or implied discussions
regarding potential future revenues from products derived there from. You
should not place undue reliance on these statements. Such forward-looking
statements reflect the current views of management regarding future events,
and involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that these tough decoy RNAs or related services will assist
the Company to achieve any particular levels of revenue in the future. In
particular, management's expectations regarding products associated with tough
decoy RNAs or related services could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally;
the Company's ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government, industry
and general public pricing pressures; the impact that the foregoing factors
could have on the values attributed to the Company's assets and liabilities as
recorded in its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the US
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website
at www.sigma-aldrich.com.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that
represents the Company's leadership in innovative biological products and
services for the global life science market and offers an array of
biologically-rich products and reagents that researchers use in scientific
investigation. Product areas include biomolecules, genomics and functional
genomics, cells and cell-based assays, transgenics, protein assays, stem cell
research, epigenetics and custom services/oligonucleotides. Sigma Life Science
also provides an extensive range critical bioessentials like biochemicals,
antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and
histology, nucleotides, amino acids and their derivatives, and cell culture
media.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in
the US and other countries. MISSION is a registered trademark of Sigma-Aldrich
Co. LLC.

SOURCE Sigma-Aldrich Corporation

Website: http://www.sigmaaldrich.com
Contact: For Sigma-Aldrich, Jen McMahon, +1-314-236-0986,
jen.mcmahon@sial.com; For Harris D. McKinney, Inc, Alan Zachary, Ph.D.,
+1-312-506-5220, azachary@harrisdmckinney.com; Ryan Ferrell, +1-312-506-5202,
rferrell@harrisdmckinney.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement